Cargando…
A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient
BACKGROUND: Some nonsteroidal anti-inflammatory drug (NSAID)-hypersensitive patients develop adverse reactions when challenged with weak cyclooxygenase 1 (COX-1) inhibitors. OBJECTIVES: To investigate the prevalence and clinical features of this high-risk population. MATERIALS AND METHODS: Patients...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650990/ https://www.ncbi.nlm.nih.gov/pubmed/23282933 http://dx.doi.org/10.1097/WOX.0b013e3181971b89 |
_version_ | 1782269144218992640 |
---|---|
author | Sánchez-Borges, Mario Capriles-Hulett, Arnaldo Caballero-Fonseca, Fernan |
author_facet | Sánchez-Borges, Mario Capriles-Hulett, Arnaldo Caballero-Fonseca, Fernan |
author_sort | Sánchez-Borges, Mario |
collection | PubMed |
description | BACKGROUND: Some nonsteroidal anti-inflammatory drug (NSAID)-hypersensitive patients develop adverse reactions when challenged with weak cyclooxygenase 1 (COX-1) inhibitors. OBJECTIVES: To investigate the prevalence and clinical features of this high-risk population. MATERIALS AND METHODS: Patients from 2 outpatient allergy clinics consulting between October 2005 and October 2007 because of adverse reactions to classic NSAIDs were submitted to confirmatory double-blind oral challenges with the suspected NSAID and with acetaminophen, preferential and/or specific COX-2 inhibitors. Patients were then classified as low-risk and high-risk groups according to the results of provocation tests. RESULTS: Three hundred three patients were studied: 179 (59.0%) were tolerant to acetaminophen and the selective COX-2 inhibitors (low-risk group), whereas 124 (40.9%) developed reactions to at least one of the ''low COX-1 inhibitors'' (high-risk group). No distinctive demographic or clinical characteristics were present when both groups of patients were compared. CONCLUSIONS: A large proportion of patients sensitive to classic NSAIDs cannot tolerate the weak COX-1 inhibitors. Oral challenges should be performed by trained specialists to advise these patients about the use of NSAIDs. |
format | Online Article Text |
id | pubmed-3650990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | World Allergy Organization |
record_format | MEDLINE/PubMed |
spelling | pubmed-36509902013-07-12 A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient Sánchez-Borges, Mario Capriles-Hulett, Arnaldo Caballero-Fonseca, Fernan World Allergy Organ J Original Research BACKGROUND: Some nonsteroidal anti-inflammatory drug (NSAID)-hypersensitive patients develop adverse reactions when challenged with weak cyclooxygenase 1 (COX-1) inhibitors. OBJECTIVES: To investigate the prevalence and clinical features of this high-risk population. MATERIALS AND METHODS: Patients from 2 outpatient allergy clinics consulting between October 2005 and October 2007 because of adverse reactions to classic NSAIDs were submitted to confirmatory double-blind oral challenges with the suspected NSAID and with acetaminophen, preferential and/or specific COX-2 inhibitors. Patients were then classified as low-risk and high-risk groups according to the results of provocation tests. RESULTS: Three hundred three patients were studied: 179 (59.0%) were tolerant to acetaminophen and the selective COX-2 inhibitors (low-risk group), whereas 124 (40.9%) developed reactions to at least one of the ''low COX-1 inhibitors'' (high-risk group). No distinctive demographic or clinical characteristics were present when both groups of patients were compared. CONCLUSIONS: A large proportion of patients sensitive to classic NSAIDs cannot tolerate the weak COX-1 inhibitors. Oral challenges should be performed by trained specialists to advise these patients about the use of NSAIDs. World Allergy Organization 2009-02-15 /pmc/articles/PMC3650990/ /pubmed/23282933 http://dx.doi.org/10.1097/WOX.0b013e3181971b89 Text en Copyright ©2009 World Allergy Organization; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Sánchez-Borges, Mario Capriles-Hulett, Arnaldo Caballero-Fonseca, Fernan A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient |
title | A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient |
title_full | A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient |
title_fullStr | A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient |
title_full_unstemmed | A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient |
title_short | A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient |
title_sort | novel phenotype of nonsteroidal anti-inflammatory drug hypersensitivity the high-risk patient |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650990/ https://www.ncbi.nlm.nih.gov/pubmed/23282933 http://dx.doi.org/10.1097/WOX.0b013e3181971b89 |
work_keys_str_mv | AT sanchezborgesmario anovelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient AT caprileshulettarnaldo anovelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient AT caballerofonsecafernan anovelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient AT sanchezborgesmario novelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient AT caprileshulettarnaldo novelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient AT caballerofonsecafernan novelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient |